Publication: Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy.
dc.contributor.author | Briongos-Figuero, Sem | |
dc.contributor.author | Estévez, Alvaro | |
dc.contributor.author | Pérez, M Luisa | |
dc.contributor.author | Martínez-Ferrer, José B | |
dc.contributor.author | García, Enrique | |
dc.contributor.author | Viñolas, Xavier | |
dc.contributor.author | Arenal, Ángel | |
dc.contributor.author | Alzueta, Javier | |
dc.contributor.author | Muñoz-Aguilera, Roberto | |
dc.date.accessioned | 2023-02-08T14:38:16Z | |
dc.date.available | 2023-02-08T14:38:16Z | |
dc.date.issued | 2019-12-11 | |
dc.description.abstract | Concerns about the prognostic value of NYHA functional class (FC) in heart failure (HF) patients carrying a prophylactic implantable cardioverter defibrillator (ICD) are still present. We aimed to compare whether mortality and arrhythmic risk were different, in a cohort of HF patients undergoing ICD-only implant, according to their FC. HF patients with left ventricle ejection fraction (LVEF) ≤35%, undergoing first prophylactic ICD-only implant were collected from a multicentre nationwide registry (2006-2015). Six hundred and twenty-one patients were identified (101 patients in NYHA I; 411 in NYHA II; 109 in NYHA III). After a mean follow-up of 4.4 years (±2.1), 126 patients died (20.3%). All-cause mortality risk was higher in symptomatic patients: 13.9% in NYHA I patients, 18.3% in NYHA II patients (HR: 1.8, 95% CI 1.1-3.2), and 32.9% in NYHA III patients (HR: 3.9, 95% CI 2.1-7.3). Seventy-eight out of all deaths were due to cardiovascular causes (12.6%). Cardiovascular mortality risk was also higher in symptomatic patients: 6.9% in NYHA I patients, 11% in NYHA II patients (HR: 2.2, 95% CI 1.1-4.9), and 23.9% in NYHA III (HR: 5.5, 95% CI 2.4-12.7). One hundred and seventeen patients received a first appropriate ICD therapy (19.4%). Arrhythmia free survival did not differ among study groups [20.8% in NYHA I patients, 18.7% in NYHA II (HR: 1.1, 95% CI 0.6-1.7) and 20.8% in NYHA III patients (HR: 1.3, 95% CI 0.7-2.5)]. NYHA class independently predicted cardiovascular mortality (NYHA III vs. NYHA I: HR, 4.7; 95% CI, 1.7-12.8, P = 0.002; NYHA II vs. NYHA I: HR, 2.1, 95% CI, 1.0-5.6, P = 0.05) but not all-cause death (NYHA III vs. NYHA I: HR: 1.8, 95% CI 0.8-3.9, P = 0.11; NYHA II vs. NYHA I: HR, 1.1, 95% CI 0.6-2.2, P = 0.71;). Atrial fibrillation, chronic kidney disease, and diabetes emerged as predictors of both all-cause death [(HR: 1.8, 95% CI 1.2-2.8, P = 0.005), (HR: 2.2, 95% CI 1.4-3.4, P Mortality in HF patients undergoing prophylactic ICD implantation was higher in symptomatic patients. NYHA functional class along with other comorbidities might be helpful to identify a subgroup of ICD carriers with poorer prognosis and higher risk of cardiovascular death. | |
dc.identifier.doi | 10.1002/ehf2.12548 | |
dc.identifier.essn | 2055-5822 | |
dc.identifier.pmc | PMC7083467 | |
dc.identifier.pmid | 31823514 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083467/pdf | |
dc.identifier.unpaywallURL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ehf2.12548 | |
dc.identifier.uri | http://hdl.handle.net/10668/14810 | |
dc.issue.number | 1 | |
dc.journal.title | ESC heart failure | |
dc.journal.titleabbreviation | ESC Heart Fail | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.page.number | 279-283 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Observational Study | |
dc.rights | Attribution-NonCommercial 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | Implantable cardioverter defibrillator | |
dc.subject | NYHA functional class | |
dc.subject | Prognosis | |
dc.subject.mesh | Cause of Death | |
dc.subject.mesh | Death, Sudden, Cardiac | |
dc.subject.mesh | Defibrillators, Implantable | |
dc.subject.mesh | Female | |
dc.subject.mesh | Follow-Up Studies | |
dc.subject.mesh | Heart Failure | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Incidence | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Primary Prevention | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Spain | |
dc.subject.mesh | Stroke Volume | |
dc.title | Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 7 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1